Skip to content
Screener

Biohaven BHVN Business Segments — G&A Share-based compensation expense

Similar metrics at other companies

OLP
OLPXReportable Segment — Share-based compensation expense
$3.52M+20.5%
Opendoor Technologies Inc logo
OPENReportable Segment — Share-based compensation expense
$105M+650%
Remitly Global, Inc. logo
RELYReportable segment — Share-based compensation expense
$34.49M-9.4%
Inseego Corp. logo
INSGReportable Segment — Share-based compensation expense
$3.05M+84.3%
BioMarin Pharmaceuticals logo
BMRNReportable Segment — G&A expenses
$253.36M+130%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Total share-based compensation expense
$16.98M+56.6%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:GeneralAndAdministrativeExpenseShareBasedCompensation.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
R&D personnel expense (excluding share-based compensation)(1)21,01221,138
R&D Share-based compensation expense18,47535,233
G&A personnel expense (excluding share-based compensation)(1)5,4556,474
G&A Share-based compensation expense9,81117,829
Other segment items (2)14,45516,951
Non-operating income(168)(493)
Provision for income taxes272609
Segment net loss130,532221,677

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's business segments — G&A share-based compensation expense?
Biohaven (BHVN) reported business segments — G&A share-based compensation expense of $9.81M in Q1 2026.
How has Biohaven's business segments — G&A share-based compensation expense changed year-over-year?
Biohaven's business segments — G&A share-based compensation expense decreased by 45.0% year-over-year, from $17.83M to $9.81M.
What is the long-term trend for Biohaven's business segments — G&A share-based compensation expense?
Over 3 years (2022 to 2025), Biohaven's business segments — G&A share-based compensation expense has grown at a -20.0% compound annual growth rate (CAGR), from $77.18M to $39.58M.
What does business segments — G&A share-based compensation expense mean?
Reflects the non-cash expense related to equity compensation for administrative and general personnel. This metric helps investors evaluate the impact of stock-based incentive programs on the company's administrative cost structure. It provides transparency into how the company rewards its non-scientific workforce.

Ask your AI about Biohaven's business segments — g&a share-based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude